IL-6 ligand blockade effective in RA

An experimental monoclonal antibody that binds to interleukin 6 (IL6) significantly reduces rheumatoid arthritis symptoms in patients who do not respond to methotrexate, Austrian researchers find.

The phase 2 study involved over 150 RA patients with active disease despite methotrexate therapy, receiving a range of doses of the drug sirukumab or placebo.

After three months, over 26% of those receiving 100mg

Latest

Trending